ENTITY
Biogen Inc

Biogen Inc (BIIB US)

132
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
bullishBiogen Inc
07 May 2025 23:39Issuer-paid

Biogen, Inc. - Steady as She Goes as the Ship Continues to Turn Slowly

Despite beating expectations with a 6% Y/Y growth in reported revenues to $2.4B (8% Y/Y growth on a constant currency basis) for 1Q25

Logo
289 Views
Share
bullishBiogen Inc
01 Apr 2025 01:22Issuer-paid

Biogen, Inc: Breakthrough Drug Developer in Reset Mode; Initiating Coverage

Biogen built its reputation on a differentiated modality-agnostic approach to drug development, deploying innovative technologies to address...

Logo
258 Views
Share
bullishBiogen Inc
22 Feb 2025 18:00

Biogen Inc.: Expansion into Immunology & Rare Diseases Is Key Diversification Strategy But Will It Work?

Biogen Inc.'s fourth-quarter and full-year 2024 financial results highlight a company in transition, balancing the challenges of competition in...

Logo
336 Views
Share
bullishBiogen Inc
09 Nov 2024 03:00

Biogen Inc.: Market Expansion & Commercial Execution Of New Launches Driving Our 'Buy' Rating! - Major Drivers

Biogen's third-quarter 2024 earnings highlighted both strides and challenges the company is navigating in its ongoing operations and strategic...

Logo
361 Views
Share
bearishMongoDB
06 May 2025 05:22

MongoDB (MDB US): Fast-Exit from Nasdaq100 in May 2025

MDB is set to be removed from Nasdaq100 on 16 May due to its low index weighting, with SHOP expected to replace it. ALNY and EBAY are potential...

Logo
1k Views
Share
x